Filing Analysis
Gossamer Bio, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release via press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 7, 2024.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Gossamer Bio received a notice from Nasdaq stating the company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days between July 30, 2024, and September 10, 2024. The company has been granted a 180-day compliance period ending March 10, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for at least 30 consecutive business days
- Potential requirement for a reverse stock split to regain compliance
📋 Key Facts
- Received written notice from Nasdaq Listing Qualifications Department on September 11, 2024.
- Failure to meet the Minimum Bid Price Requirement (Nasdaq Listing Rule 5450(a)(1)).
- Compliance period expires March 10, 2025.
- To regain compliance, stock must close at $1.00 or higher for 10 consecutive business days before the deadline.
- Failure to comply may lead to a transfer to Nasdaq Capital Market or delisting.
Gossamer Bio, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notification of the release of quarterly earnings via press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Report date: August 12, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Signed by Bryan Giraudo, Chief Operating Officer and Chief Financial Officer.
Gossamer Bio, Inc. has received notification from Nasdaq confirming it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. This resolves a previous deficiency notice issued on May 22, 2024.
🚩 Red Flags
- Previous history of delisting risk due to low share price (minimum $1.00 requirement).
📋 Key Facts
- The Company has regained compliance with Nasdaq Listing Rule 5450(a)(1).
- The minimum bid price matter is now officially closed as of July 18, 2024.
- The previous non-compliance was due to the common stock failing to maintain a $1.00 minimum bid price for 30 consecutive business days.
Gossamer Bio, Inc. reported the results of its annual meeting of stockholders held on June 6, 2024. The meeting included the election of directors and advisory votes on auditor selection and executive compensation.
📋 Key Facts
- Skye Drynan was elected to serve as a Class II director for a three-year term expiring in 2027 (161,240,706 votes 'For').
- John Quisel, Ph.D., J.D., was elected to serve as a Class III director for a three-year term expiring in 2027 (161,260,707 votes 'For').
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Stockholders approved, on an advisory basis, the compensation of the Company's named executive officers (115,985,182 votes 'For').
Gossamer Bio received a notice from Nasdaq stating the company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days between April 10, 2024, and May 21, 2024. The company has been granted a 180-day compliance period ending November 18, 2024.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Potential necessity of a reverse stock split to regain compliance
- Risk of being moved from the Nasdaq Global Select Market to the Nasdaq Capital Market
📋 Key Facts
- Received written notice from Nasdaq Listing Qualifications Department on May 22, 2024.
- Failure to meet the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)).
- Compliance period expires on November 18, 2024.
- To regain compliance, stock must close at or above $1.00 for 10 consecutive business days before the deadline.
- Failure to comply may lead to a transfer to Nasdaq Capital Market or delisting.
Gossamer Bio, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Report date: May 7, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Signed by Bryan Giraudo, Chief Operating Officer and Chief Financial Officer.
Gossamer Bio entered into a global collaboration and license agreement with Chiesi Farmaceutici S.p.A to develop and commercialize seralutinib for PAH and PH-ILD. The deal includes significant upfront payments, milestones, and an equity option for Chiesi.
🚩 Red Flags
- Equity Option: Provides a potential dilutive mechanism via private placement if certain triggers (Phase 3 completion, tender offer, or change of control) occur.
- Concentration Risk: The company's financial upside is heavily tied to the success and commercialization efforts of a single partner (Chiesi).
📋 Key Facts
- Chiesi agreed to pay Gossamer $160 million as reimbursement for development costs.
- Gossamer is eligible for up to $146 million in regulatory milestones and $180 million in sales milestones.
- The agreement includes an 'Equity Option' allowing Chiesi to purchase shares at 107.5% of the 30-day VWAP (minimum $1.63/share) up to a 9.9% ownership stake.
- Gossamer will lead global development and US commercialization for PAH and PH-ILD, while sharing costs equally with Chiesi (except for the PROSERA Phase 3 study).
- The company successfully terminated its existing Credit Facility with MidCap Financial Trust as part of this transaction.
Gossamer Bio, Inc. announced the appointment of two new independent directors to its Board: Skye Drynan and Steven Nathan, M.D., effective March 11, 2024.
📋 Key Facts
- Skye Drynan appointed as Class III director; former Partner/Senior BioPharma Analyst at Capital Group.
- Steven Nathan, M.D. appointed as Class I director; Medical Director of Inova Health System’s Advanced Disease Program.
- Both directors will receive an annual cash retainer of $40,000.
- Each director was granted options to purchase 230,000 shares of common stock, vesting monthly over three years.
- The Board determined both appointees are independent per Nasdaq Global Select Market requirements.
Gossamer Bio, Inc. issued a press release on March 5, 2024, reporting its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Reporting period: Quarter and Fiscal Year ended December 31, 2023.
- Report date: March 5, 2024.
- The filing is an announcement of earnings results via press release (Exhibit 99.1).
Gossamer Bio, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This resolves the deficiency notice previously issued by Nasdaq on October 19, 2023.
🚩 Red Flags
- Historical delisting risk (previously non-compliant with minimum bid requirement).
📋 Key Facts
- The Company received a letter from Nasdaq confirming it has regained compliance with Nasdaq Listing Rule 5450(a)(1).
- The minimum bid price matter is now considered closed.
- Compliance was achieved after the stock failed to maintain a $1.00 minimum price for 30 consecutive business days as of October 2023.